Acumen Pharmaceuticals announced it will report Q4 and year-end 2025 financial results on March 26, 2026, with a conference call at 8:00 a.m. ET. The clinical-stage biopharmaceutical company is advancing sabirnetug (ACU193), a monoclonal antibody targeting amyloid beta oligomers for Alzheimer's disease treatment, currently in Phase 2 trials.

Acumen Pharmaceuticals announced that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on March 18, 2026. The clinical-stage biopharmaceutical company is advancing sabirnetug (ACU193), a monoclonal antibody targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment, currently in Phase 2 trials following positive Phase 1 results.

Halozyme Therapeutics raised its 2026 and multi-year financial guidance, projecting total revenue growth of 23-30% year-over-year to $1.71-$1.81 billion. Royalty revenue is expected to exceed $1 billion in 2026, growing 30-35%, one year ahead of previous projections. The company acquired Surf Bio for $300 million and forecasts adjusted EBITDA of $1.125-$1.205 billion, with non-GAAP diluted EPS of $7.75-$8.25.

Emerging immunotherapy technologies are transforming treatment for gastrointestinal cancers, with companies developing novel combination strategies to activate immune responses in historically resistant tumors. The global cancer immunotherapy market is projected to reach $443.17 billion by 2030.

Renaissance Group initiated a new $35.11 million position in Halozyme Therapeutics, acquiring 478,735 shares representing 1.32% of its U.S. equity assets. The biotech company offers innovative drug delivery technology and has demonstrated strong financial performance with consistent sales growth.

Acumen Pharmaceuticals will report its Q3 2025 financial results on November 12, 2025, hosting a conference call and webcast to provide a business and financial update. The company is developing a novel therapeutic targeting toxic amyloid beta oligomers for Alzheimer's disease treatment.

Pharmaceutical company argenx presented clinical trial data demonstrating VYVGART's effectiveness in treating generalized myasthenia gravis across different patient subtypes, including seronegative patients, with promising results in symptom reduction and steroid use management.

A Phase 1b/2 study of subcutaneous amivantamab in recurrent or metastatic head and neck cancer demonstrated a 45% overall response rate, with rapid and durable tumor responses in patients who had previously progressed on checkpoint inhibitors and chemotherapy.

New data from the Phase 3 MARIPOSA study shows that amivantamab plus lazertinib significantly reduces EGFR and MET resistance mutations compared to osimertinib monotherapy in first-line advanced non-small cell lung cancer treatment.

Acumen Pharmaceuticals will participate in two upcoming investor conferences in September 2025, presenting its ongoing research into Alzheimer's disease treatment using sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid beta oligomers.

Halozyme Therapeutics reported strong Q2 2025 financial results, with non-GAAP EPS of $1.54 (69% YoY growth) and revenue of $325.7 million (41% YoY increase). The company raised full-year guidance and continues to leverage its ENHANZE drug delivery technology through pharmaceutical partnerships.

Acumen Pharmaceuticals will report Q2 2025 financial results on August 12, 2025, and host a conference call to provide a business and financial update, focusing on their Alzheimer's disease therapeutic candidate sabirnetug.